From: Linda Carlton <[log in to unmask]>
To: [log in to unmask]
Subject:
http://207.155.63.2/medscape/cgi-bin/taos_doc.pl?msw+0+med93-95+490843+query+(reduced-glutathione)
Date: Tue, 25 Mar 1997 02:40:20 -0800
[ Search and Display Medscape Full-Text Articles ]
Please use your Browser's 'BACK' button to return to the listing
Title: Alterations in glutathione levels in Parkinson's disease and other
neurodegenerative disorders affecting basal ganglia [see comments]
Title Abreviation: Ann Neurol Date of Pub: 1994 Sep
Author: Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner
P; Marsden CD;
Issue/Part/Supplement: 3 Volume Pagination: 348-55
Issue: 36
MESH Headings: Aged; Aged, 80 and over; Atrophy (ME); Basal Ganglia
Diseases (ME); Brain (*ME); Brain Diseases (ME); Female; Glutathione
(AA/*ME); Human; Huntington's Disease (ME); Male; Middle Age; Nervous
System Diseases (*ME); Parkinson Disease (*ME); Support, Non-U.S. Gov't;
Supranuclear Palsy, Progressive (ME); -RN-;
Journal Title Code: 6AE Publication Type: JOURNAL ARTICLE
Date of Entry: 941004N Entry Month: 9412
Country: UNITED STATES Index Priority: 1
Language: Eng Unique Identifier: 94361464
Unique Identifier:
94361464 ISSN: 0364-5134
Abstract: Reduced glutathione (GSH) and oxidized glutathione (GSSG) levels
were measured in various brain areas (substantia nigra, putamen, caudate
nucleus, globus pallidus, and cerebral cortex) from patients dying with
Parkinson's disease, progressive supranuclear palsy, multiple-system
atrophy, and Huntington's disease and from control subjects with no
neuropathological changes in substantia nigra. GSH levels were reduced in
substantia nigra in Parkinson's disease patients (40% compared to control
subjects) and GSSG levels were marginally (29%) but insignificantly
elevated; there were no changes in other brain areas. The only significant
change in multiple-system atrophy was an increase of GSH (196%) coupled
with a reduction of GSSG (60%) in the globus pallidus. The only change in
progressive supranuclear palsy was a reduced level of GSH in the caudate
nucleus (51%). The only change in Huntington's disease was a reduction of
GSSG in the caudate nucleus (50%). Despite profound nigral cell loss in
the substantia nigra in Parkinson's disease, multiple-system atrophy, and
progressive supranuclear palsy, the level of GSH in the substantia nigra
was significantly reduced only in Parkinson's disease. This suggests that
the change in GSH in Parkinson's disease is not solely due to nigral cell
death, or entirely explained by drug therapy, for multiple-system atrophy
patients were also treated with levodopa. The altered GSH/GSSG ratio in
the substantia nigra in Parkinson's disease is consistent with the concept
of oxidative stress as a major component in the pathogenesis of nigral
cell death in Parkinson's disease.
Abstract By: Author
Address: Parkinson's Disease Society Experimental Research Laboratories,
Pharmacology Group, Biomedical Sciences Division, King's College London,
UK.
